Shanghai Pharmaceutical (601607.SH): Metoclopramide hydrochloride injection passed generic drug consistency evaluation
Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, the company's holding subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (...
Shanghai Pharmaceutical (601607.SH): Sacubatl Valsartan sodium tablets approved for production
On May 14, Ge Longhui Pharmaceutical (601607.SH) announced that the company's holding subsidiary Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as “Changzhou Pharmaceutical Factory”) has received the “Drug Registration Certificate” (certificate numbers: 2024S00767, 2024S00768) issued by the State Drug Administration, and the drug has been approved for production. Sacubatl valsartan sodium tablets are mainly used to treat symptoms such as chronic heart failure and primary hypertension.
Changes in Hong Kong stocks | Shanghai Pharmaceutical (02607) rose more than 5% in the afternoon, I031 tablets approved for clinical trials, approved for production of injectable methotrexate
Shanghai Pharmaceutical (02607) rose more than 5% in the afternoon. As of press release, it rose 4.26% to HK$12.72, with a turnover of HK$76.06 million.
Shanghai Pharmaceuticals Gets Regulatory Nod to Trial Tumor Drug
Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) will conduct clinical trials on the I031 tablets after receiving approval from China's National Medical Products Administration, the company sai
Shanghai Pharmaceutical (601607.SH): I031 received clinical trial approval notice
Gelonghui, May 13 | Shanghai Pharmaceutical (601607.SH) announced that the “I031 tablets” independently developed by the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. I031 is a small molecule inhibitor that can inhibit tumor proliferation. Preclinical studies have shown that I031 can inhibit tumor growth in animal models of human tumors. The project was independently developed by Shanghai Pharmaceutical, and the company has full intellectual property rights.
A subsidiary of Novizan (688105.SH) and a subsidiary of Shanghai Pharmaceutical reached a cooperation on businesses such as Alzheimer's disease blood test products
Novi Zan (688105.SH) announced that Nanjing Novi Zan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (“Novi...
Does Shanghai Pharmaceuticals Holding (SHSE:601607) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved
Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%
Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) attributable profit rose 1.62% year over year to 1.54 billion yuan in the first quarter from 1.52 billion yuan, according to separate filings
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Shanghai Pharmaceutical (02607.HK) net profit of 1,542 billion yuan in the first quarter increased 1.62% year-on-year
Gelonghui, April 26 | Shanghai Pharmaceutical (02607.HK) announced that in the first quarter of 2024, during the reporting period, the company's main business grew steadily, achieving operating revenue of 70.153 billion yuan (currency is RMB, same below), an increase of 5.93% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 6.944 billion yuan, a year-on-year decrease of 10.98%; the pharmaceutical business achieved sales revenue of 63.209 billion yuan, an increase of 8.19% over the previous year. During the reporting period, the company achieved net profit attributable to shareholders of listed companies of 1,542 billion yuan, an increase of 1.62% over the previous year. Among them, the industrial business contributed profit
上海醫藥:2024年第一季度報告
上海醫藥:2023 年年報
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
Damo: Target price for Shanghai Pharmaceuticals “gain” rating reduced to HK$17
Morgan Stanley released a research report stating that it lowered the target price of Shanghai Pharmaceuticals (02607) by 5.6%, from HK$18 to HK$17, and lowered the company's profit forecast for 2024-2030 by 2%-9%. The main reason was the decline in sales in the manufacturing sector, but the rating still “increased”, mainly due to the complete integration of the platform (manufacturing, distribution, retail) to provide a synergy effect.
Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17
DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.
Private Companies in Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 4.8% Last Week
Key Insights Significant control over Shanghai Pharmaceuticals Holding by private companies implies that the general public has more power to influence management and governance-related decisions Th
UBS: Target price of HK$14.9 for the initial “buy” rating for Shanghai pharmaceuticals
UBS released a research report stating that it initially gave Shanghai Pharmaceuticals (02607) a “buy” rating, with a target price of HK$14.9. Shanghai Pharmaceutical is the second-largest pharmaceutical distributor in China. It accounts for about 9.5% of the market share in 2022. It is optimistic that it has the potential to have differentiated one-stop distribution services and its own pipeline for the production of new drugs. It is predicted that the compound annual growth rate of revenue and profit will reach 10% and 10.6% from 2024 to 2026. Potential positive catalysts include approval of new drugs, strong drug sales expectations, and signing new exclusive distribution agreements with international pharmaceutical companies.
Shanghai Pharmaceutical (02607.HK) held a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16 | Shanghai Pharmaceutical (02607.HK) announced that the board of directors meeting will be held on April 26, 2024 (Friday) to approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
No Data